glp 1 mechanism of action Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic Discovery of GLP-1–Based Drugs for

FDA approves Jardiance (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

A study of health insurance claims found a 44% reduction in hospitalizations for GLP-1 users

As its use becomes more widespread, perioperative physicians and head-neck surgeons must be familiar with its pharmacokinetics and associated risks

These trials also demonstrated a significant reduction in C-Reactive Protein (CRP) levels, reinforcing the hypothesis that suppressing the pro-inflammatory state may yield substantial clinical benefits in this patient population

GLP-1 agonists are a class of injectable medications that are used for type 2 diabetes and weight management